(CDNA) CareDx, Inc BCG Matrix Research

AlloSeq cfDNA platform fits the Star bucket because it extends CareDx, Inc beyond single-organ testing into broader donor-derived cell-free DNA surveillance, which is the main growth lane in transplant monitoring. Its platform angle matters: one assay can support kidney, heart, and lung follow-up, so it can scale faster than narrow tests.

• Broader multi-organ surveillance
• Aligned with fastest-growing biomarker use
• Platform breadth supports Star status

TruSight HLA NGS is CareDx, Inc’s high-resolution HLA typing test built on next-generation sequencing, which supports tighter donor-recipient matching and smoother transplant workflows. As molecular typing adoption rises, it fits a Star profile: strong growth with a strategic role in transplant care.

• NGS-based, high-resolution HLA typing
• Improves matching accuracy
• Supports transplant workflow speed
• Benefits from molecular typing growth

Ottr transplant software fits Cash Cow because it is workflow software for transplant patient management, so revenue is tied to an installed base and repeat use, not heavy new-customer push. CareDx, Inc has said its software and services model is lower-growth than diagnostics, but it also needs less marketing spend and supports steady recurring sales.

• Installed-base revenue drives repeat use
• Lower marketing intensity supports margins
• Growth is slower than diagnostics
• Recurring workflow use fits Cash Cow status

XynQAPI quality tracking software fits CareDx, Inc. as a Cash Cow because it serves a steady, recurring transplant-program need: quality tracking and waitlist management, not fast user growth. CareDx does not break out 2025/2026 revenue for XynQAPI, so the clearest read is its stable institutional use inside a mature transplant workflow. That kind of embedded software usually supports low-churn, high-retention revenue.

• Steady use in transplant programs
• Mature need, not rapid expansion
• Likely low churn, high retention
• No separate 2025/2026 disclosure

AlloSeq Tx HLA typing is a high-resolution lab test in a crowded market, but it sits on a smaller base than CareDx's main HLA franchise. Its limited scale and slower share gains point to Dog status in a BCG view. In plain terms, it adds niche utility, but it is not a major growth driver.

• High-resolution, but crowded segment
• Smaller than core HLA business
• Weak growth and share support Dog

Legacy HLA reagent kits are an older, commoditized line in CareDx, Inc’s portfolio, with pricing pressure that keeps margins thin. Growth is slower than NGS-based typing, so these kits fit the Dogs bucket in the BCG Matrix: low share, low growth, and limited capital appeal. CareDx’s 2025 mix still shows the market moving toward higher-value molecular testing, which leaves legacy reagents as a fading cash drag.

• Older, commoditized HLA typing
• Slower growth than NGS
• Low margin and pricing pressure
• Weak BCG fit: Dog

AlloCare engagement upgrades look like a Question Mark because digital transplant support can scale fast, but today it still contributes far less than CareDx's core diagnostics business. If adoption rises, the platform can grow quickly, yet low current share means it needs more proof before it can move toward a Star.

• High growth, low share
• Adoption is the key lever
• Value still trails diagnostics

AI driven transplant analytics is still a newer adjacency for CareDx, and its 2025 monetization looks early versus the core diagnostics base. The addressable need is real because transplant care is data heavy, but share is still low and traction is not yet proven, so it fits Question Marks. If adoption scales, it could become a growth lever; if not, it stays a niche add on.

• New adjacency, early revenue
• Low share, uncertain traction
• High upside, but unproven